You are here: Home: BCU 2 | 2006: Harold J Burstein, MD, PhD: Select publications

SELECT PUBLICATIONS

Carlson RW et al. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw 2006;4(Suppl 1):1-26. Abstract

Dang C et al. Preliminary cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/ neu overexpressed/Amplified breast cancer (BCA). San Antonio Breast Cancer Symposium 2005;Abstract 2041.

HERA Study Team. Trastuzumab (H: Herceptin®) following adjuvant chemotherapy (CT) significantly improves disease-free survival (DFS) in early breast cancer (BC) with HER2 overexpression: The HERA Trial. San Antonio Breast Cancer Symposium 2005;Abstract 11.

Hillner BE. Clinical and cost-effectiveness implications of the adjuvant trastuzumab in HER2+ breast cancer trials. San Antonio Breast Cancer Symposium 2005;Abstract 5040.

Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005;353(16):1734-6. No abstract available

Joensuu H et al; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20. Abstract

Joensuu H et al. Trastuzumab in combination with docetaxel or vinorelbine as adjuvant treatment of breast cancer: the FinHer Trial. San Antonio Breast Cancer Symposium 2005;Abstract 2.

Kabe KL, Kolesar JM. Role of trastuzumab in adjuvant therapy for locally invasive breast cancer. Am J Health Syst Pharm 2006;63(6):527-33. Abstract

Kim C et al. Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo. San Antonio Breast Cancer Symposium 2005;Abstract 46.

Perez EA et al. Exploratory analysis from NCCTG N9831: Do clinical and laboratory characteristics predict cardiac toxicity of trastuzumab when administered as a component of adjuvant therapy? San Antonio Breast Cancer Symposium 2005;Abstract 2038.

Piccart-Gebhart MJ et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659-72. Abstract

Press MF et al. Topoisomerase II-alpha gene amplification as a predictor of responsiveness to anthracycline-containing chemotherapy in the Cancer International Research Group 006 clinical trial of trastuzumab (herceptin) in the adjuvant setting. San Antonio Breast Cancer Symposium 2005;Abstract 1045.

Ragaz J, Spinelli JJ. Cost-benefit estimates of adjuvant (Adj) trastuzumab (herceptin, H) for early breast cancer (BrCa). San Antonio Breast Cancer Symposium 2005;Abstract 2029.

Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract

Slamon D et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. San Antonio Breast Cancer Symposium 2005;Abstract 1.

Tan-Chiu E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23(31):7811-9. Abstract


Home · Search


Terms and Conditions of Use and General Disclaimer
Copyright © 2006 Research To Practice. All Rights Reserved